A clinical trial has revealed a new Alzheimer’s drug can successfully slow down decline in memory and thinking by 35 per cent. Donanemab has been shown to significantly reduce cognitive decline in people with early-stage Alzheimer’s disease. The trial by US pharmaceutical company Eli Lilly showed it has been successful in removing sticky amyloid plaques […]